Showing 47 results
-
Media Release /The approval of Ilaris (canakinumab) in the treatment of adult-onset Still’s disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening…
-
Media Release /Expansion of treatment centre network includes two specialized centres in Alberta certified to deliver Kymriah to Canadian patients with relapsed/refractory (r/r) pediatric and young adult B-cell…
-
Media Release /Open feedback by Novartis associates contributed to coveted Canadian employer recognition Novartis ranked among the companies with the highest levels of trust and most inclusive cultures in the…
-
Media Release /Kesimpta® (ofatumumab) delivers superior efficacy with a favourable safety profile and can be self-administered at home, addressing a significant unmet need for people living with relapsing…
-
Media Release /KISQALI® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners…
-
Media Release /June 18, 2020 – Dorval - Novartis Pharmaceuticals Canada Inc. is pleased to announce the filing of a marketing application to Health Canada for AVXS-101 (onasemnogene abeparvovec), known in the US…
-
Media Release /More than half of patients with BRAF-mutated advanced melanoma treated with Tafinlar + Mekinist were alive and free of a relapse at five years1 Study conclusions drawn from the five-year follow-up…
